{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/FSGS"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FSGS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","market":"US","secType":"STK","nameCN":"First Trust SMID Growth Strength ETF","latestPrice":29.0407,"timestamp":1750104000000,"preClose":28.797,"halted":0,"volume":347,"delay":0,"floatShares":1000002,"shares":1000002,"eps":0,"marketStatus":"Post-Mkt","change":0.2437,"latestTime":"06-16 19:33:43 EDT","open":29.1,"high":29.1,"low":29.0407,"amount":10097.89,"amplitude":0.002059,"askPrice":43.59,"askSize":200,"bidPrice":14.53,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1750118400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":28.797,"sharesOutstanding":1000002,"nav":29.34,"aum":29340058.68,"dividendRate":0.02617,"bidAskSpread":0,"volumeRatio":0.223094},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FSGS\",,,,,undefined,":{"symbol":"FSGS","floatShares":1000002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.223094,"shares":1000002,"dividePrice":0.76,"high":29.1,"amplitude":0.002059,"preClose":28.797,"low":29.0407,"week52Low":24.39,"pbRate":"--","week52High":32.96,"institutionHeld":0,"latestPrice":29.0407,"eps":0,"divideRate":0.02617,"volume":347,"delay":0,"ttmEps":0,"open":29.1,"prevYearClose":29.7151,"prevWeekClose":28.797,"prevMonthClose":29.1468,"prevQuarterClose":27.34,"fiveDayClose":29.6116,"twentyDayClose":29.6,"sixtyDayClose":27.4795},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/FSGS\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FSGS\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535138002","title":"Press Release: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2535138002","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535138002?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:01","pubTimestamp":1747252860,"startTime":"0","endTime":"0","summary":"MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026. MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025. Strong Balance Sheet with $294.4 Million in Cash and Cash Equivalents, Expected to Provide Cash Runway into H2 2027. SOUTH SAN FRANCISCO, Calif., May 14, 2025  -- Maze Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today reported financial results for the first quarter ended March 31, 2025, and reiterated upcoming milestones.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE","FSGS"],"gpt_icon":0},{"id":"2533803576","title":"Press Release: Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2533803576","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533803576?lang=en_us&edition=fundamental","pubTime":"2025-05-06 20:00","pubTimestamp":1746532800,"startTime":"0","endTime":"0","summary":"-- On track to announce the primary endpoint results from the atacicept. pivotal Phase 3 ORIGIN trial in IgA Nephropathy  in 2Q 2025;planning for Biologics License Application  submission for atacicept. -- Expanded atacicept development program across multiple autoimmune kidney. \"We are rapidly approaching a significant Vera milestone with the upcoming primary endpoint results from the pivotal atacicept ORIGIN 3 trial, and if successful, we expect this to enable a BLA submission to the FDA in the second half of this year, which may allow approval and commercial launch in 2026. If approved, we believe that atacicept has the potential to advance the standard of care in IgA nephropathy,\" said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. \"The Vera team is well-positioned to build on the success of the lead atacicept development program in IgAN, with the expansion into additional potential indications in other autoimmune kidney diseases and beyond.\". -- Plan to submit a Bio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655156.SGD","LU0417517546.SGD","LU0942090050.USD","FSGS","LU1732800096.USD","LU1244550494.USD","LU0868494617.USD","IE00BJTD4N35.SGD","IE0004445015.USD","LU0912757837.SGD","LU1718418525.SGD","IE00BJTD4V19.USD","BK4209","LU0256863811.USD","IE00BJJMRX11.SGD","LENZ","LU1732799900.SGD","BK4539","IE00BFSS7M15.SGD","LU0795875086.SGD","IE00B7KXQ091.USD","BK4610","IE00BFSS8Q28.SGD","LU1244550577.SGD","LU2279689827.SGD","BK4550","LU0795875169.SGD","BK4588","BK4213","LU1585245621.USD","IE00BJJMRY28.SGD","PMN","LU2133065610.SGD","TACI","VERA","BK4504","BK4007","BK4581","LU1430594728.SGD","BK4139","BKV","LU0868494708.USD","BK4585","BK4534","LU1244550221.USD","BK4566"],"gpt_icon":1},{"id":"2532108840","title":"Guess which ASX All Ords stock is rocketing 58% on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2532108840","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532108840?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:13","pubTimestamp":1746062011,"startTime":"0","endTime":"0","summary":"The share market may be struggling to get into gear on Thursday but that isn't stopping one ASX All Ords stock from racing higher. In morning trade, its shares are up a massive 58% to 76 cents thanks to some big news. Which ASX All Ords stock is rocketing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/01/guess-which-asx-all-ords-stock-is-rocketing-58-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","LU2065169927.USD","FSGS","BK7067","BK7501","LU2065171402.SGD","LU2065171311.SGD","DXB.AU","LU2065170008.USD","FOLD","BK7508"],"gpt_icon":0},{"id":"2532014900","title":"Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532014900","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532014900?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:02","pubTimestamp":1746061329,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) and Amicus Therapeutics entered into an exclusive license agreement for the commercialization of Dimerix's drug candidate DMX-200 in the US, according to a Thursday Australian bourse","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DMX","BK7067","FSGS","BK7501","DXB.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":13,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FSGS\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FSGS","amount":0.3931,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"FIRST TRUST EXCHANGE-TRADED FUND VI FIRST TRUST SMID GROWTH STRENGTH ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FSGS\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":0.3931,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FSGS\",market:\"US\",delay:false,,,undefined,":{}}}